BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24607627)

  • 1. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling.
    Li J; Yang XM; Wang YH; Feng MX; Liu XJ; Zhang YL; Huang S; Wu Z; Xue F; Qin WX; Gu JR; Xia Q; Zhang ZG
    J Hepatol; 2014 Jun; 60(6):1225-34. PubMed ID: 24607627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase A activity and norepinephrine level in hippocampus determine hyperwheel running in SPORTS rats.
    Morishima M; Harada N; Hara S; Sano A; Seno H; Takahashi A; Morita Y; Nakaya Y
    Neuropsychopharmacology; 2006 Dec; 31(12):2627-38. PubMed ID: 16421512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.
    Cheng Y; Hou T; Ping J; Chen T; Yin B
    J Exp Clin Cancer Res; 2018 Sep; 37(1):228. PubMed ID: 30219064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
    Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
    Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues.
    Pang YY; Li JD; Gao L; Yang X; Dang YW; Lai ZF; Liu LM; Yang J; Wu HY; He RQ; Huang ZG; Xiong DD; Yang LH; Shi L; Mo WJ; Tang D; Lu HP; Chen G
    Cancer Med; 2020 Nov; 9(21):8004-8019. PubMed ID: 32931665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
    Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
    Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
    Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
    Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.
    Yang X; Liang L; Zhang XF; Jia HL; Qin Y; Zhu XC; Gao XM; Qiao P; Zheng Y; Sheng YY; Wei JW; Zhou HJ; Ren N; Ye QH; Dong QZ; Qin LX
    Hepatology; 2013 Jul; 58(1):158-70. PubMed ID: 23389848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
    Schaefer KL; Wada K; Takahashi H; Matsuhashi N; Ohnishi S; Wolfe MM; Turner JR; Nakajima A; Borkan SC; Saubermann LJ
    Cancer Res; 2005 Mar; 65(6):2251-9. PubMed ID: 15781638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
    Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
    Ma WL; Hsu CL; Yeh CC; Wu MH; Huang CK; Jeng LB; Hung YC; Lin TY; Yeh S; Chang C
    Hepatology; 2012 Jul; 56(1):176-85. PubMed ID: 22318717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brucine, an alkaloid from seeds of Strychnos nux-vomica Linn., represses hepatocellular carcinoma cell migration and metastasis: the role of hypoxia inducible factor 1 pathway.
    Shu G; Mi X; Cai J; Zhang X; Yin W; Yang X; Li Y; Chen L; Deng X
    Toxicol Lett; 2013 Oct; 222(2):91-101. PubMed ID: 23933019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation.
    Liu J; Liu H; Zhang W; Wu Q; Liu W; Liu Y; Pan D; Xu J; Gu J
    Glycobiology; 2013 Sep; 23(9):1097-109. PubMed ID: 23811795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
    Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
    Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
    Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
    Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
    Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
    Fuchs BC; Fujii T; Dorfman JD; Goodwin JM; Zhu AX; Lanuti M; Tanabe KK
    Cancer Res; 2008 Apr; 68(7):2391-9. PubMed ID: 18381447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.